TuHURA Biosciences Total Long Term Liabilities 2010-2024 | HURA

TuHURA Biosciences total long term liabilities from 2010 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.

TuHURA Biosciences Total Long Term Liabilities 2010-2024 | HURA

TuHURA Biosciences total long term liabilities from 2010 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$171.8B
Vertex Pharmaceuticals (VRTX)$122.6B
Gilead Sciences (GILD)$109.8B
Bristol Myers Squibb (BMY)$107B
Regeneron Pharmaceuticals (REGN)$106.1B
CSL (CSLLY)$96.1B
GSK (GSK)$78.8B
Alnylam Pharmaceuticals (ALNY)$38.1B
Argenex SE (ARGX)$34B
Biogen (BIIB)$27.1B
BioNTech SE (BNTX)$26.4B
Illumina (ILMN)$22.9B
BeiGene (BGNE)$21.5B
Moderna (MRNA)$20.5B
Genmab (GMAB)$15.1B
BioMarin Pharmaceutical (BMRN)$13.4B
Exact Sciences (EXAS)$13B
Insmed (INSM)$12.7B
Incyte (INCY)$12.6B
Vaxcyte (PCVX)$12.6B
Sarepta Therapeutics (SRPT)$12.2B
Bio-Techne Corp (TECH)$11.1B
QIAGEN (QGEN)$9.6B
Bio-Rad Laboratories (BIO.B)$9.3B
Roivant Sciences (ROIV)$8.7B
Exelixis (EXEL)$8.2B
Legend Biotech (LEGN)$8.2B
Intra-Cellular Therapies (ITCI)$8.1B
Repligen (RGEN)$8.1B
Revolution Medicines (RVMD)$7.9B